Reuters: IPOX® Associate Muehlbauer on Agomab’s Nasdaq Debut Amid Biotech Selectivity

A recent Reuters article reports on the Nasdaq debut of Agomab Therapeutics, a Belgium-based biopharmaceutical company, which secured a valuation of $716.4 million. Despite raising $200 million by selling 12.5 million shares at $16 apiece, the company's stock opened lower at $14.70, reflecting a broader trend of investor selectivity in the current IPO landscape.

The piece highlights that while biopharmaceutical firms are returning to the public markets after a quiet 2025, recent volatility in the software and data-services sectors, driven by AI-related disruption fears, has made investors more cautious. Agomab, which focuses on treatments for fibrostenosing Crohn’s disease and other inflammatory conditions, managed to navigate this window even as other listings in the tech space faced postponements.

IPOX® Research Associate Lukas Muehlbauer was featured in the article, providing analysis on the current divergence between sector sentiments and the specific hurdles facing clinical-stage companies.

"Investors are more cautious about clinical-stage companies that do not yet have products on the market. However, the fact that the listing went ahead proves that the window for drugmakers remains open, even while it is effectively closed for software firms."

Read the full article by Prakhar Srivastava on Reuters: Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut